You don't have to live like this.
A: Stress urinary incontinence is defined as the involuntary leakage of urine. The problem afflicts approximately 18 million adults in the United States, 85% of them being women. You are not alone! It usually takes four to six years to see a healthcare professional for this condition.
Q: What is SUI?
For more information, visit the FDA's Urogynecologic Surgical Mesh Implants website at http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/ImplantsandProsthetics/ UroGynSurgicalMesh/default.htm A: One condition is called hypermobility, "hyper" means too much and "mobility" refers to movement, which can result from childbirth, previous pelvic surgery or hormonal changes. Hypermobility occurs when the normal pelvic floor muscles can no longer provide the necessary support to the urethra. This may lead to the urethra dropping when any downward pressure is applied, resulting in involuntary leakage.
Another condition is called intrinsic sphincter deficiency, also sometimes referred to as ISD. This refers to the weakening of the urethral sphincter muscles or closing mechanism. As a result, the sphincter does not function normally regardless of the position of the bladder neck or urethra.
Q: What type of SUI do I have?
A weakening of the muscles supporting the urethra causes the urethra to drop during physical activity, resulting in urine leaking.
Normal functioning anatomy
Frequently Asked Questions Down-to-Earth Answers A: Your minimally invasive sling procedure is estimated to only take 30 -45 minutes. Your doctor will determine the type of anesthesia you will have during the procedure. Once the anesthesia takes effect, your doctor will begin the procedure.
A small incision will be made in the vaginal area. Next, the synthetic mesh implant is placed to create a "sling" of support under the urethra.
When your doctor is satisfied with the position of the mesh, he or she will close and bandage the small incisions in the groin area (if applicable for your sling type) and the top of the vaginal canal.
Q: How will my surgery be performed?
A: Stress urinary incontinence can be treated in several ways, depending on the exact nature of the incontinence and its severity. Q: What are the potential risks and complications of surgery?
A: As with most surgical procedures, there are potential risks and complications associated with this SUI surgery. Your physician can further explain your specific risks based on your medical history and surgical approach used. Some potential adverse reactions related to surgical correction for stress urinary incontinence include:
Removal of mesh or correction of mesh related complications may involve multiple surgeries. For any questions on these potential complications, or additional information listed at the end of the brochure, please ask your doctor.
Q: What should I expect after surgery?
A: Before you are discharged from the hospital, you may be given a prescription for an antibiotic and/or pain medication to relieve any discomfort you may experience. You will be instructed on how to care for your incision area. At the discretion of your physician, most patients resume moderate activities within 2 to 4 weeks, with no strenuous activity for up to 6 weeks.
Most patients resume moderate activities within 2 to 4 weeks... A: In 2011, the U.S. Food and Drug Administration issued a public health notification which reported higher than expected complication rates with synthetic mesh delivered through vaginal incisions for the treatment of pelvic organ prolapse.
Although complications from mid-urethral slings used for the treatment of stress urinary incontinence were NOT included in the FDA Public Health notification, FDA gathered an expert panel of physicians to debate the clinical evidence supporting the use of vaginal mesh for both pelvic organ prolapse and stress urinary incontinence.
In January 2012, an FDA panel recommended additional clinical studies to evaluate the safety and effectiveness of mesh used to treat POP. For traditional mid-urethral slings, "the panel consensus was that the safety and effectiveness of these devices is well established and post market studies for these devices are not necessary". "The panel consensus was that the safety and effectiveness of mini-slings is not well understood and that premarket evaluation of new mini-slings should be supported by clinical studies 1 ".
It is important to know that the FDA has never recalled these devices from the market. These devices are cleared for use in the United States.
The clinical studies requested by the FDA for mini-slings are currently underway. In addition to these studies, as an example, there are more than 35 clinical publications supporting the use of Boston Scientific mid-urethral sling products for the treatment of stress urinary incontinence. As a result, since 2002, over 750,000 patients have been treated worldwide with Boston Scientific mid-urethral slings.
Bulking Procedure in which a bulking agent is injected under the urethra and bladder neck to treat stress urinary incontinence.
Hypermobility A condition associated with stress urinary incontinence in which loss of urethral support and stability impacts ability of the urethra to close during a stress event.
Intrinsic Sphincter
Refers to the weakening of the urethral sphincter Deficiency ("ISD") muscles or closing mechanism.
Minimally Invasive A procedure that minimizes surgical incisions and Surgery reduces trauma to the body.
Pelvic Floor
A group of muscles that form at the base of the pelvis and support pelvic organs.
The surgical repair of prolapse and incontinence. Reconstruction Pelvic Organ Prolapse A medical condition that occurs when normal support of the vagina is lost resulting in the "sagging" or "dropping" of pelvic organs.
Pessary
A removable plastic device that is inserted into the vagina to hold prolapsed organs back in place.
Retropubic
Procedure used to treat stress incontinence by Colposuspension suspending a sagging bladder neck and urethra to the pubic bone.
Retropubic Sling
Refers to surgical delivery of a traditional mid-urethral Placement sling which includes both transvaginal and abdominal incisions, leaving a graft material suspending the bladder neck and extending behind the pubic bone.
Single Incision
Refers to surgical delivery of a mini mid-urethral sling (Mini) Sling Placement through a single vaginal incision.
Stress Urinary
The involuntary loss of urine during physical activity, Incontinence which may include but is not limited to: coughing, laughing, or lifting.
Traditional Mesh Slings Refers to a full length sling that utilizes the ingrowth of surrounding tissue to remain in place and support the urethra to reduce stress urinary incontinence.
Transobturator Sling
Refers to surgical delivery of a traditional mid-urethral Placement sling which includes transvaginal and groin incisions, leaving a graft material suspending the bladder neck and extending through the obturator regions.
Transvaginal Surgery Surgery that is approached through an incision in the vagina.
Urethra
Tube that carries urine from the bladder outside of the body.
Sphincter Muscle
Muscles in the urethra that squeeze together and prevent urine from escaping the body involuntarally.
Frequently Asked Questions Down-to-Earth Answers Glossary Voiding Diary Example
CONSIDERATIONS PRIOR TO SURGICAL REPAIR
If you are considering surgery for stress urinary incontinence your physician may ask you questions about your medical history, to ensure you are a candidate for this type of procedure. Some of these contraindications, warnings/ potential complications, and adverse events associated with stress urinary incontinence are listed below as a reference to you. You should consult your physician for a complete understanding of this information and to determine whether this procedure is right for you.
INTENDED USE / INDICATIONS FOR USE
The mesh implant is intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from urethral hypermobility and/or intrinsic sphincter deficiency.
CONTRAINDICATIONS
A mesh implant is contraindicated in the following patients:
• Pregnant patients, patients with the potential for future growth or patients who are considering future pregnancies.
• Any patients with soft tissue pathology into which the implant is to be placed.
• Patients with any pathology that would compromise implant placement.
• Patients with any pathology, such as blood supply limitations or infections that would compromise healing.
ADVERSE EVENTS:
• Local irritation at the wound site and/or a foreign body response may occur.
• Erosion/exposure/extrusion of the mesh through the vaginal or urethral mucosa, bladder wall or other surrounding tissue Erosion (presence of mesh material within the organs surrounding the vagina) Extrusion (presence of mesh material within the vagina).
-Scarring/scar contracture (tightening of tissue) -Device migration (implant moves from the original implantation site) -Fistula formation (a hole/passage that develops through the wall of organs) -Inflammation (redness, heat, pain or swelling resulting from surgery) The occurrence of these events may require surgical intervention and possible removal of the entire mesh.
• Like all foreign bodies, the mesh may potentiate an existing infection.
• Excess tension may cause temporary or permanent lower urinary tract obstruction and retention. 
